Health-Related Quality of Life in Mild-Moderate Patchy Alopecia Areata: Results from the First Controlled Phase 2 Clinical Trial with STS01 (Dithranol/ProSilic) and Future Challenges

A phase 2, randomized, double-blind, placebo-controlled trial investigated the effects of STS01, a topical formulation of dithranol, on mild to moderate patchy alopecia areata (AA). The study found significant, dose-related improvements in hair regrowth. However, these improvements did not lead to significant enhancements in health-related quality of life (HRQoL), even for patients who experienced complete hair regrowth. The study highlighted challenges in measuring HRQoL, such as the lack of a true baseline, the development of coping mechanisms by patients, and potential delays between physical and psychological improvements.